Due to the beneficial impact of MR antagonists regarding cardiovascular morbidity/mortality after acute MI, and the local forebrain depletion of MR/GR in our study, one struggles to advise against MR (or GR) antagonism in the clinical setting of comorbid depression after MI. The gene discussed is NR3C1; the disease is major depressive disorder.